Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events. We retrospectively describe the impact of immune checkpoi...

Full description

Bibliographic Details
Main Authors:	Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-02-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1177/2045894021992236

Similar Items

Relationship of left ventricular outflow tract velocity time integral to treatment strategy in submassive and massive pulmonary embolism
by: David Antoine, et al.
Published: (2020-09-01)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
by: Manuel Morgado, et al.
Published: (2020-10-01)

Ocular adverse events with immune checkpoint inhibitors
by: Tony Fang, et al.
Published: (2019-09-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Cui TM, et al.
Published: (2020-11-01)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
by: Vanina Vani, et al.
Published: (2020-04-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
by: Dorothy M. Gujral, PhD, et al.
Published: (2020-02-01)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
by: Zheng-Hang Wang, et al.
Published: (2018-03-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
by: Hasan Ahmad Hasan Albitar, et al.
Published: (2020-01-01)

Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy
by: Aurelija Abraityte, et al.
Published: (2017-06-01)

A novel mouse model for checkpoint inhibitor-induced adverse events.
by: Kieran Adam, et al.
Published: (2021-01-01)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
by: Uday N. Shivaji, et al.
Published: (2019-11-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
by: Yoshiyuki Nakamura
Published: (2019-05-01)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
by: Myriam Delaunay, et al.
Published: (2019-11-01)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
by: Ciro Manzo
Published: (2021-01-01)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
by: Charles Dolladille, et al.
Published: (2020-06-01)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
by: Min Wang, et al.
Published: (2021-07-01)

Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
by: I. V. Menshikova, et al.
Published: (2020-09-01)

The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy
by: Fangning Rong, et al.
Published: (2020-01-01)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
by: Xiao-Hui Jia, et al.
Published: (2020-12-01)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
by: Kalyan R. Chitturi, DO, et al.
Published: (2019-12-01)

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
by: Gerard Milano, et al.
Published: (2021-01-01)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
by: Sharvesh Raj Seeruttun
Published: (2019-10-01)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
by: Satya Das, et al.
Published: (2019-11-01)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
by: Eva Kassi, et al.
Published: (2019-11-01)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021-04-01)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
by: Jessica Castrillon Lal, et al.
Published: (2021-05-01)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
by: Andrew L Mammen, et al.
Published: (2021-07-01)

MAGGIC Risk Model Predicts Adverse Events and Left Ventricular Remodeling in Non-Ischemic Dilated Cardiomyopathy
by: Dong Y, et al.
Published: (2020-12-01)

Baer in Posthemorrhagic Ventricular Dilatation
by: J Gordon Millichap
Published: (1989-04-01)

Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
by: Nora Möhn, et al.
Published: (2020-01-01)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
by: Josefien W. Hommes, et al.
Published: (2021-02-01)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
by: Maria Stelmachowska-Banaś, et al.
Published: (2020-10-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Cannot write session to /tmp/vufind_sessions/sess_h59d5blfqdbq7gfj02sshqtshv